Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ViiV Healthcare
With
GlaxoSmithKline
Primary Purpose
Other: This study will assess the impact of a light meal, a standard meal, and a high fat meal on the pharmacokinetics (PK) of BMS-955176 micronized crystalline (MC) tablet at a dose of 180 mg relative to fasted conditions.
Age
18–50
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examinations, vital sign measurements, 12-lead ECG measurements, and clinical laboratory test results
Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive. BMI = Weight (kg)/\[Height (m)\]2
Men and women, ages 18 to 50 years, inclusive
Women must not be of childbearing potential, must not be breastfeeding
You may not be if
Any significant acute or chronic medical illness
History of cardiac disease or clinically significant cardiac arrhythmias
Current or recent (within 3 months of study drug administration) gastrointestinal disease
Any major surgery within 4 weeks of study drug administration
Any gastrointestinal surgery (including cholecystectomy) that could impact upon the absorption of study drug
